Gsk (GLAXF) Other Non-Current Liabilities (2009 - 2026)

Gsk's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at -$1.4 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 8.08% year-over-year to -$1.4 billion; the TTM figure through Mar 2026 stood at -$1.4 billion (down 8.08% YoY), while the FY2025 annual figure was -$1.3 billion, down 195.93% from the prior year.
• Other Non-Current Liabilities was -$1.4 billion for Q1 2026 at Gsk, down from -$1.4 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.4 billion in Q4 2024 to a low of -$1.4 billion in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged -$756.1 million across 5 years, with a median of -$1.3 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 99.26% in 2022, then sank 13367.05% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $1.1 billion in 2022, then jumped by 30.3% to $1.4 billion in 2023, then increased by 2.76% to $1.4 billion in 2024, then sank by 196.38% to -$1.4 billion in 2025, then declined by 3.04% to -$1.4 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at -$1.4 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.4 billion (Q3 2025), per Business Quant data.